[European guidelines on heart failure: pharmacotherapy].
In: Herz, Jg. 48 (2023-03-01), Heft 2, S. 89-94
Online
academicJournal
Zugriff:
The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transporter 2 (SGLT2) inhibitors are now recommended as early as possible after diagnosis. Completing the substance groups has priority over increasing the dosage of the individual substances. This makes it necessary to rethink current clinical practice, especially as the guidelines are reluctant to give concrete instructions for implementation.
(© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
Titel: |
[European guidelines on heart failure: pharmacotherapy].
|
---|---|
Autor/in / Beteiligte Person: | Grundmann, S ; von Zur Mühlen C |
Link: | |
Zeitschrift: | Herz, Jg. 48 (2023-03-01), Heft 2, S. 89-94 |
Veröffentlichung: | Munchen : Urban Und Vogel ; <i>Original Publication</i>: München, Urban & Schwarzenberg., 2023 |
Medientyp: | academicJournal |
ISSN: | 1615-6692 (electronic) |
DOI: | 10.1007/s00059-022-05157-z |
Schlagwort: |
|
Sonstiges: |
|